XML 39 R25.htm IDEA: XBRL DOCUMENT v3.19.1
17. Subsequent Event (Notes)
12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events [Text Block] 17. SUBSEQUENT EVENT

On March 4, 2019, we acquired all the issued and outstanding stock of a small commercial-stage company for approximately $20 million. We believe this acquisition will complement our offerings of life science products. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business acquisition. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process.

We are presently unable to report the purchase price allocation or the evaluation of the transaction, as more time is needed to complete the information transfer from the seller and include all information into a valuation of individual assets and liabilities.